NASDAQ:ALLK Allakos - ALLK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.61 -0.12 (-2.54%) (As of 03/24/2023 08:50 PM ET) Add Compare Share Share Today's Range$4.51▼$4.7850-Day Range$4.61▼$8.1152-Week Range$2.54▼$8.73Volume757,300 shsAverage Volume978,975 shsMarket Capitalization$394.98 millionP/E RatioN/ADividend YieldN/APrice Target$14.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Allakos MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside220.0% Upside$14.75 Price TargetShort InterestBearish7.63% of Float Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.24) to ($2.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector324th out of 995 stocksPharmaceutical Preparations Industry141st out of 482 stocks 3.2 Analyst's Opinion Consensus RatingAllakos has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.75, Allakos has a forecasted upside of 220.0% from its current price of $4.61.Amount of Analyst CoverageAllakos has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.63% of the float of Allakos has been sold short.Short Interest Ratio / Days to CoverAllakos has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allakos has recently increased by 39.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllakos does not currently pay a dividend.Dividend GrowthAllakos does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAllakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Allakos is -0.86. Previous Next 1.9 News and Social Media Coverage News SentimentAllakos has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Allakos this week, compared to 2 articles on an average week.Search Interest8 people have searched for ALLK on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allakos insiders have not sold or bought any company stock.Percentage Held by Insiders33.25% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.07% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allakos are expected to grow in the coming year, from ($2.24) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allakos is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allakos is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllakos has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Allakos (NASDAQ:ALLK) StockAllakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.Read More Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLK Stock News HeadlinesMarch 10, 2023 | msn.comWhere Allakos Stands With AnalystsMarch 10, 2023 | msn.comWhy Allakos Stock Was Heating Up TodayMarch 27, 2023 | Weiss Ratings (Ad)Banking NightmareDuring and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …March 6, 2023 | finance.yahoo.comAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsJanuary 26, 2023 | finance.yahoo.comIs Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic ValueDecember 15, 2022 | finance.yahoo.comIs Allakos (NASDAQ:ALLK) In A Good Position To Deliver On Growth Plans?December 9, 2022 | finance.yahoo.comAllakos Inc. (ALLK) Moves to Buy: Rationale Behind the UpgradeNovember 29, 2022 | finance.yahoo.comAllakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications BiologyMarch 27, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...November 10, 2022 | finance.yahoo.comAllakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual MeetingNovember 7, 2022 | finance.yahoo.comAllakos Provides Business Update and Reports Third Quarter 2022 Financial ResultsOctober 24, 2022 | reuters.comALLK.OQ - Allakos Inc | Stock Price & Latest News | ReutersOctober 20, 2022 | finance.yahoo.comPharmaEssentia USA Expands Leadership With Executive Hires in Marketing, Medical Affairs and Communications and Advocacy - Yahoo FinanceOctober 18, 2022 | seekingalpha.comAllakos: Potential For Comeback With Lirentelimab With 2 Indications (NASDAQ:ALLK) - Seeking AlphaOctober 14, 2022 | barrons.comAlkermes, Allakos, and Other Stocks See Action From Activist Investors - Barron'sSeptember 27, 2022 | marketwatch.comAllakos Shares Rise After Co. Says Chmn, Director Buy Shares - MarketWatchSeptember 26, 2022 | uk.investing.comAdobe And 2 Other Stock Insiders Are Buying By Benzinga - Investing.com UKSeptember 24, 2022 | finance.yahoo.comAfter losing 95% in the past year, Allakos Inc. (NASDAQ:ALLK) institutional owners must be relieved by the recent gainSeptember 21, 2022 | investorplace.comWhy Is Allakos (ALLK) Stock Soaring 25% Today? - InvestorPlaceSeptember 20, 2022 | benzinga.comWhy Allakos Shares Are Rising Sharply - Allakos (NASDAQ:ALLK) - BenzingaSeptember 19, 2022 | seekingalpha.comIceCure Medical, Allakos top healthcare gainers; Virios Therapeutics lead losers' pack - Seeking AlphaSeptember 19, 2022 | uk.investing.comWhy Allakos Shares Are Rising Sharply By Benzinga - Investing.com UKSeptember 19, 2022 | investorplace.comWhy Is Allakos (ALLK) Stock Soaring 25% Today?September 19, 2022 | marketwatch.comAllakos Shares Surge After Public Offering >ALLK - MarketWatchSeptember 19, 2022 | seekingalpha.comAllakos prices ~$150M underwritten offering - Seeking AlphaSeptember 19, 2022 | finance.yahoo.comAllakos Announces Pricing of $150 Million Underwritten Offering of Common StockSeptember 12, 2022 | finance.yahoo.comAllakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLK Company Calendar Last Earnings3/06/2023Today3/27/2023Next Earnings (Estimated)5/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLK CUSIPN/A CIK1564824 Webwww.allakos.com Phone(650) 597-5002FaxN/AEmployees192Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.75 High Stock Price Forecast$22.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+220.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($5.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-319,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-112.53% Return on Assets-87.80% Debt Debt-to-Equity RatioN/A Current Ratio10.28 Quick Ratio10.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.64 per share Price / Book1.27Miscellaneous Outstanding Shares85,680,000Free Float57,193,000Market Cap$394.98 million OptionableNot Optionable Beta0.50 Key ExecutivesRobert AlexanderChief Executive Officer & DirectorAdam L. TomasiPresidentScott HirschChief Operating OfficerHarlan Baird RadfordChief Financial OfficerCraig PatersonChief Medical OfficerKey CompetitorsConcert PharmaceuticalsNASDAQ:CNCECOMPASS PathwaysNASDAQ:CMPSLexicon PharmaceuticalsNASDAQ:LXRXEmergent BioSolutionsNYSE:EBSArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsState of Wisconsin Investment BoardBought 63,727 shares on 2/15/2023Ownership: 0.075%Legal & General Group PlcBought 16,956 shares on 2/15/2023Ownership: 0.020%E Fund Management Co. Ltd.Bought 16,749 shares on 2/15/2023Ownership: 0.020%Boothbay Fund Management LLCBought 11,515 shares on 2/15/2023Ownership: 0.014%Schonfeld Strategic Advisors LLCBought 10,280 shares on 2/15/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions ALLK Stock - Frequently Asked Questions Should I buy or sell Allakos stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares. View ALLK analyst ratings or view top-rated stocks. What is Allakos' stock price forecast for 2023? 5 brokerages have issued 1 year price objectives for Allakos' stock. Their ALLK share price forecasts range from $7.00 to $22.00. On average, they predict the company's share price to reach $14.75 in the next year. This suggests a possible upside of 220.0% from the stock's current price. View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts. How have ALLK shares performed in 2023? Allakos' stock was trading at $8.42 on January 1st, 2023. Since then, ALLK shares have decreased by 45.2% and is now trading at $4.61. View the best growth stocks for 2023 here. When is Allakos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. View our ALLK earnings forecast. How were Allakos' earnings last quarter? Allakos Inc. (NASDAQ:ALLK) posted its quarterly earnings data on Monday, March, 6th. The company reported ($0.50) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.50). What ETFs hold Allakos' stock? ETFs with the largest weight of Allakos (NASDAQ:ALLK) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA SmallCap Momentum ETF (DWAS), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and BlackRock Future Health ETF (BMED). What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS). When did Allakos IPO? (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager. What is Allakos' stock symbol? Allakos trades on the NASDAQ under the ticker symbol "ALLK." Who are Allakos' major shareholders? Allakos' stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (1.47%), Braidwell LP (1.08%), Millennium Management LLC (0.98%), Geode Capital Management LLC (0.85%), Renaissance Technologies LLC (0.79%) and Citigroup Inc. (0.74%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James. View institutional ownership trends. How do I buy shares of Allakos? Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allakos' stock price today? One share of ALLK stock can currently be purchased for approximately $4.61. How much money does Allakos make? Allakos (NASDAQ:ALLK) has a market capitalization of $394.98 million. The company earns $-319,950,000.00 in net income (profit) each year or ($5.53) on an earnings per share basis. How many employees does Allakos have? The company employs 192 workers across the globe. How can I contact Allakos? Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com. This page (NASDAQ:ALLK) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.